* Cohance Lifesciences' Board approves fund infusion into its subsidiary, NJ Bio Inc, USA. * The investment will be up to USD 10 million (₹83 crore approx.) through Compulsorily Convertible Preferred Stock. * The funds will support NJ Bio Inc.'s growth initiatives, including capital expenditure (capex). * Further details will be disclosed after the subsidiary's board approval.
